AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$URGN

Smith Jason Drew sold $65K of URGN

Smith Jason Drew (General Counsel) sold 1,519 shares of UroGen Pharma Ltd. (URGN) at $42.54 on 2026-09-08.

Original reporting
SEC EDGAR · Smith Jason Drew
Published Sep 9, 2026, 6:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$URGN
Neutral
high confidence
Mentioned
$URGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$URGNNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market effect.

02

Market read

Minor relevance; informs investors of insider activity but unlikely to move the stock.

03

What to watch

Potential upcoming clinical data could influence insider behavior.

Relevance 3/10Novelty 4/10Timing: filed Sep 9, 2026 (post‑market)

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$URGNNeutralHigh confidence
Context

General Counsel sold 1,519 shares for $64.6K, reducing his stake to 53,141 shares.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to market cap and insider remains a large holder.

Market effects

Sector

None; biotech sector not affected by a single insider sale.

Regional

No regional impact.

Global

Low relevance to global markets.

Counterpoint

What could challenge this read

Insider may be diversifying; could signal confidence if other insiders are buying.

Key entities

  • person
    Smith Jason Drew

    General Counsel of UroGen Pharma Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

URGN insider trading history →

Related articles

SEP 23
$URGNHighAI 8/10

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

UroGen Pharma (URGN) signed a deal with IntraGel Therapeutics, investing up to $7M for rights to develop oncology products and potentially acquire TumoCure. URGN's ZUSDURI generated $50.4M in Q2 2026 revenue, up 73% QoQ, with strong prescriber retention and patent protection extended to 2044. UGN-103 is on track for NDA submission in Q3 2026, and UGN-501 will begin Phase 1 trials in Q4 2026.

yahoo.com2 min
SEP 9
$URGNMed

UroGen Pharma general counsel sells $64,618 in shares

UroGen Pharma's (URGN) General Counsel, Jason Drew Smith, sold 1,519 shares for $64,618 and acquired 3,334 shares via restricted stock units. URGN reported Q2 2026 revenue of $72.5M, beating estimates, driven by its bladder-cancer drug ZUSDURI. Guggenheim raised its price target to $58, while H.C. Wainwright set a $75 target.

investing.com2 min